vs
Apellis Pharmaceuticals, Inc.（APLS）与Montrose Environmental Group, Inc.（MEG）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Montrose Environmental Group, Inc.的1.0倍（$199.9M vs $193.3M），Montrose Environmental Group, Inc.净利率更高（-4.3% vs -29.5%，领先25.2%），Montrose Environmental Group, Inc.同比增速更快（2.2% vs -5.9%），Montrose Environmental Group, Inc.自由现金流更多（$46.5M vs $-14.3M），过去两年Montrose Environmental Group, Inc.的营收复合增速更高（11.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
蒙特罗斯环境集团是一家美国跨国企业，主营各类环境服务，业务覆盖环境行业全产业链，可为公共部门及私营领域客户提供一体化支持。公司总部位于阿肯色州小石城，在美国特拉华州完成注册。
APLS vs MEG — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $193.3M |
| 净利润 | $-59.0M | $-8.2M |
| 毛利率 | — | 38.6% |
| 营业利润率 | -25.6% | -1.3% |
| 净利率 | -29.5% | -4.3% |
| 营收同比 | -5.9% | 2.2% |
| 净利润同比 | -62.2% | 70.9% |
| 每股收益（稀释后） | $-0.40 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $193.3M | ||
| Q3 25 | $458.6M | $224.9M | ||
| Q2 25 | $178.5M | $234.5M | ||
| Q1 25 | $166.8M | $177.8M | ||
| Q4 24 | $212.5M | $189.1M | ||
| Q3 24 | $196.8M | $178.7M | ||
| Q2 24 | $199.7M | $173.3M | ||
| Q1 24 | $172.3M | $155.3M |
| Q4 25 | $-59.0M | $-8.2M | ||
| Q3 25 | $215.7M | $8.4M | ||
| Q2 25 | $-42.2M | $18.4M | ||
| Q1 25 | $-92.2M | $-19.4M | ||
| Q4 24 | $-36.4M | $-28.2M | ||
| Q3 24 | $-57.4M | $-10.6M | ||
| Q2 24 | $-37.7M | $-10.2M | ||
| Q1 24 | $-66.4M | $-13.4M |
| Q4 25 | — | 38.6% | ||
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 40.8% | ||
| Q3 24 | — | 40.9% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 37.8% |
| Q4 25 | -25.6% | -1.3% | ||
| Q3 25 | 48.7% | 4.4% | ||
| Q2 25 | -18.6% | 6.4% | ||
| Q1 25 | -50.0% | -5.9% | ||
| Q4 24 | -12.3% | -12.1% | ||
| Q3 24 | -24.0% | -0.6% | ||
| Q2 24 | -14.7% | -1.5% | ||
| Q1 24 | -36.0% | -6.5% |
| Q4 25 | -29.5% | -4.3% | ||
| Q3 25 | 47.0% | 3.7% | ||
| Q2 25 | -23.6% | 7.8% | ||
| Q1 25 | -55.3% | -10.9% | ||
| Q4 24 | -17.1% | -14.9% | ||
| Q3 24 | -29.2% | -5.9% | ||
| Q2 24 | -18.9% | -5.9% | ||
| Q1 24 | -38.5% | -8.6% |
| Q4 25 | $-0.40 | $-0.13 | ||
| Q3 25 | $1.67 | $0.21 | ||
| Q2 25 | $-0.33 | $0.42 | ||
| Q1 25 | $-0.74 | $-0.64 | ||
| Q4 24 | $-0.30 | $-0.91 | ||
| Q3 24 | $-0.46 | $-0.39 | ||
| Q2 24 | $-0.30 | $-0.39 | ||
| Q1 24 | $-0.54 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $11.2M |
| 总债务越低越好 | — | $277.1M |
| 股东权益账面价值 | $370.1M | $451.2M |
| 总资产 | $1.1B | $981.3M |
| 负债/权益比越低杠杆越低 | — | 0.61× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $11.2M | ||
| Q3 25 | $479.2M | $6.7M | ||
| Q2 25 | $370.0M | $10.5M | ||
| Q1 25 | $358.4M | $30.3M | ||
| Q4 24 | $411.3M | $12.9M | ||
| Q3 24 | $396.9M | $13.0M | ||
| Q2 24 | $360.1M | $16.9M | ||
| Q1 24 | $325.9M | $9.5M |
| Q4 25 | — | $277.1M | ||
| Q3 25 | — | $302.4M | ||
| Q2 25 | — | $264.6M | ||
| Q1 25 | — | $235.6M | ||
| Q4 24 | — | $204.8M | ||
| Q3 24 | — | $233.0M | ||
| Q2 24 | — | $188.7M | ||
| Q1 24 | $93.1M | $280.9M |
| Q4 25 | $370.1M | $451.2M | ||
| Q3 25 | $401.2M | $458.7M | ||
| Q2 25 | $156.3M | $470.3M | ||
| Q1 25 | $164.2M | $444.1M | ||
| Q4 24 | $228.5M | $446.3M | ||
| Q3 24 | $237.1M | $449.2M | ||
| Q2 24 | $264.3M | $448.8M | ||
| Q1 24 | $266.7M | $324.5M |
| Q4 25 | $1.1B | $981.3M | ||
| Q3 25 | $1.1B | $985.7M | ||
| Q2 25 | $821.4M | $998.1M | ||
| Q1 25 | $807.3M | $992.2M | ||
| Q4 24 | $885.1M | $990.4M | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $943.9M | ||
| Q1 24 | $831.9M | $918.1M |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.42× | ||
| Q1 24 | 0.35× | 0.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $51.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $46.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 24.1% |
| 资本支出强度资本支出/营收 | 0.1% | 2.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $91.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $51.9M | ||
| Q3 25 | $108.5M | $28.1M | ||
| Q2 25 | $4.4M | $21.9M | ||
| Q1 25 | $-53.4M | $5.5M | ||
| Q4 24 | $19.4M | $32.0M | ||
| Q3 24 | $34.1M | $11.4M | ||
| Q2 24 | $-8.3M | $894.0K | ||
| Q1 24 | $-133.0M | $-22.0M |
| Q4 25 | $-14.3M | $46.5M | ||
| Q3 25 | $108.3M | $22.3M | ||
| Q2 25 | $4.4M | $19.9M | ||
| Q1 25 | $-53.4M | $2.4M | ||
| Q4 24 | $19.3M | $29.7M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | $-8.4M | $-9.8M | ||
| Q1 24 | $-133.3M | $-29.3M |
| Q4 25 | -7.1% | 24.1% | ||
| Q3 25 | 23.6% | 9.9% | ||
| Q2 25 | 2.5% | 8.5% | ||
| Q1 25 | -32.0% | 1.3% | ||
| Q4 24 | 9.1% | 15.7% | ||
| Q3 24 | — | 5.7% | ||
| Q2 24 | -4.2% | -5.6% | ||
| Q1 24 | -77.3% | -18.9% |
| Q4 25 | 0.1% | 2.8% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.8% | ||
| Q4 24 | 0.0% | 1.2% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 6.1% | ||
| Q1 24 | 0.2% | 4.7% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.36× | ||
| Q2 25 | — | 1.19× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MEG
暂无分部数据
